Anesiva's media center is designed to provide reporters with easy access to news about the company and its products for stories in development. If you don't find what you are looking for or need more information, please contact us.
| All Releases |
|---|
 |
Corgentech Completes Enrollment of Pivotal Phase 3 Trial Studying E2F Decoy, a Novel Vascular Therapy
Oct 1, 2003
|
54.8 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Oct. 1, 2003 -- Corgentech Inc., a privately held biotechnology company, announced today that the company has completed patient enrollment in a second pivotal Phase 3 clinical trial to evaluate its lead product, CGT003, a first-of-its-kind E2F Decoy treatment for the prevention of graft failure following perip...
|
|
|
Corgentech Will Present at the UBS Warburg Global Life Sciences Conference
Sep 19, 2003
|
50.1 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2003 -- Corgentech Inc., a privately held biotechnology company, today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the upcoming UBS Warburg Global Life Sciences Conference. His presentation will be held on Tuesday, September 23 at 2:00 p.m....
|
|
|
Corgentech Completes Enrollment of Pivotal Phase 3 Trial Studying E2F Decoy in Coronary Artery Bypass Graft Failure
Sep 18, 2003
|
54.5 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2003 -- Corgentech Inc., a privately held biotechnology company, announced today that the company has completed patient enrollment in a pivotal Phase 3 clinical trial to evaluate its lead product, CGT003, a first-of-its-kind E2F Decoy therapy for the prevention of graft failure following coronary art...
|
|
|
Corgentech Appoints Daniel Gennevois, M.D., Vice President of Medical Affairs
Sep 10, 2003
|
51.5 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2003 -- Corgentech Inc., a privately-held biotechnology company, announced today that Daniel Gennevois, M.D., has been appointed vice president of medical affairs. Dr. Gennevois has held a number of top clinical positions with leading biotechnology and pharmaceutical companies, including Roche Bios...
|
|
|
Corgentech Completes Move to New Headquarters in South San Francisco
Jun 30, 2003
|
50.7 KB
|
| |
SOUTH SAN FRANCISCO, Calif., June 30, 2003 -- Corgentech Inc., a privately-held biotechnology company, announced today that it has moved its corporate headquarters from Palo Alto to new space at 650 Gateway Boulevard in South San Francisco, CA 94080, effective today.
The new South San Francisco headquarters doubles the company's ...
|
|
|
Click here to download our most recent fact sheet.